Actuate Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies centered on GSK-3β inhibition through its lead asset elraglusib, a proprietary small-molecule ATP-competitive inhibitor designed to block a master regulator of oncogenic signaling pathways. The company is advancing elraglusib across multiple cancer indications, including metastatic pancreatic ductal adenocarcinoma as its most advanced program, as well as pediatric cancers and solid tumors, with both intravenous and oral formulations in development. Actuate exclusively licenses the elraglusib technology from academic institutions and generates value through clinical validation and potential regulatory approvals, with revenue anticipated from product commercialization once approved, while maintaining a lean operating structure supported by equity financing and operating primarily as a semi-virtual organization.